Charles River Laboratories Intl. Inc vs Lumen Technologies Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while Lumen Technologies Inc trades at $5.3 (market cap $5.73B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.5× Lumen Technologies Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Lumen Technologies Inc for 40 Days on average.
| CRL | LUMN | |
|---|---|---|
Market Cap | $14.23B | $5.73B |
Volume | 1,176,885 | 17,079,799 |
Sector | Health | Media |
52-Week High | $310.77 | $11.83 |
52-Week Low | $149.93 | $5.53 |
Typical Hold Time | 33 Days | 40 Days |
Enterprise Value | $17.06B | $17.35B |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
LUMN trades at $5.20, down 12.01% in 24 hours, reflecting bearish technical signals and negative profitability. Revenue declined to $12.40B in 2025 with a net loss of $1.74B, though recent product launches like Intelligent Internet target AI-driven growth. The stock faces high debt levels at $17.49B long-term, while analyst consensus is predominantly Hold (60.71%) with a Reduce rating average.
The outlook remains challenged by legacy revenue declines and substantial debt, but strategic pivots to AI networking offer speculative upside. Key risks include persistent losses and competitive pressures, requiring careful monitoring of cash flow and execution on new initiatives for any sustained recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →